Agenus announced that GlaxoSmithKline and Agenus have amended the QS-21 license and manufacturing agreement to include additional rights for the use of Agenus’ proprietary QS-21 Stimulon adjuvant in GSK Biologicals’ adjuvant systems.
In addition, Agenus has agreed to grant the vaccines company the first right to negotiate for the purchase of Agenus or certain of its assets.
The first right to negotiate will expire after five years. Under the terms of the agreement, GSK will pay Agenus a non-refundable payment of $9 million, of which $2.5 million is creditable against future manufacturing technology transfer royalty payments.
The agreement also includes royalty payments for an undisclosed indication upon commercialization of a vaccine product.
“Today’s announcement further validates QS-21 as a key adjuvant while expanding its potential use in another important indication,” stated Garo Armen, Ph.D., chairman and CEO of Agenus. “With over a dozen clinical programs in development containing our adjuvant, we are pleased to be able to contribute to the future development of a broad range of vaccines.”
Buy the on-demand report Partnering Agreements with GlaxoSmithKline
See further deal information at Current Agreements (subscription required)